The simultaneous Form 144 filings by a major venture capital insider (Atlas Venture) and a director (John Cox) signal a strong bearish sentiment from those closest to the company. Traders should consider reducing long positions or establishing shorts, as this coordinated selling often precedes a decline. Monitor for any subsequent Form 4 filings confirming the sales, and watch for any negative pipeline or regulatory news that may have prompted this insider activity.
Price Chart
Executive Summary
Atlas Venture Fund XI, L.P., a major venture capital insider, filed a Form 144 on August 13, 2026, indicating intent to sell 268,354 shares of Dyne Therapeutics (DYN) with an approximate market value of $7.0 million. Separately, Director John Cox also filed a Form 144 on the same day, signaling a proposed sale. The Atlas Venture sale represents a significant insider liquidation by a founding investor, which is a bearish signal for the stock, especially given the company's pre-revenue status and reliance on pipeline catalysts. The batch of filings on the same day amplifies the negative sentiment, suggesting coordinated insider selling.
Key Facts
- Atlas Venture Fund XI, L.P. filed Form 144 to sell 268,354 shares of DYN, valued at approximately $7.0 million based on the filing date.
- Director John Cox also filed a Form 144 on the same day, indicating a proposed sale of an undisclosed number of shares.
- The Atlas Venture sale represents a significant portion of their holdings, as they are a founding venture capital investor.
- The filing date is August 13, 2026, with the proposed sale to occur on or after that date.
- The company has a market cap of $4.9B and a 90% bullish analyst consensus, but is a pre-revenue biotech.
Financial Impact
Atlas Venture proposes to sell $7.0M worth of DYN common stock. Director John Cox's proposed sale amount is undisclosed.
Risk Factors
- Form 144 is an intent to sell; the actual sale may not occur or may be for a smaller amount.
- The company is pre-revenue, making it highly sensitive to pipeline and regulatory catalysts, which could overshadow insider selling.
- High short interest or a positive catalyst could lead to a short squeeze, counteracting the bearish signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (DYN) — Batch item 1 | 0001628280-26-056843 |
| Document: 0001628280-26-056843-index.html | 0001628280-26-056843 |
| Document: 0001628280-26-056843.txt | 0001972481-26-000260 |
| 144 Filing (DYN) — Batch item 4 | 0001628280-26-056843 |
| Document: 0001628280-26-056843-index.html | 0001628280-26-056843 |
| 144 Filing (DYN) — Batch item 6 | 0001972481-26-000260 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Insider Cluster | $26.15 $17.90 | ▲ +31.55% | ▲ +29.57% | $15.39 (+41.15%) |
Aug 14, 2026 6w ago | 144 | $26.15 $18.52 | ▼ −29.18% | ▼ −27.65% | $15.39 (−41.15%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▲ +27.94% | ▲ +25.95% | $15.39 (+40.12%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.39 (−40.12%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.39 (−40.12%) |
Jul 29, 2026 9w ago | Press Release | $25.73 $26.09 | ▲ +1.40% | ▼ −2.57% | $15.39 (−40.19%) |
Jul 22, 2026 10w ago | Press Release | $23.21 $26.78 | ▼ −15.38% | ▼ −12.48% | $15.39 (+33.69%) |
Jul 20, 2026 10w ago | 8-K | $23.45 $26.15 | ▲ +11.51% | ▲ +7.39% | $15.39 (−34.37%) |
Jun 30, 2026 13w ago | Insider Cluster | $21.79 $25.10 | ▲ +15.19% | ▲ +17.38% | $15.39 (−29.37%) |
Jun 29, 2026 13w ago | 144 | $22.21 $25.63 | ▼ −15.40% | ▼ −16.43% | $15.39 (+30.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access